Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation

Livia Hegerova, Adam Bachan, Qing Cao, Huong X. Vu, John Rogosheske, Mark T Reding, Claudio G Brunstein, Mukta Arora, Celalettin Ustun, Gregory M Vercellotti, Veronika Bachanova

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Catheter-related thrombosis (CRT) occurs frequently during autologous hematopoietic cell transplantation (AHCT) and data regarding the incidence, risk factors, and management are understudied. We evaluated 789 consecutive patients with lymphoma and myeloma that underwent AHCT over 10 years (2006 to 2016) and detected the incidence of CRT was 6.3%; only 32% of CRT were symptomatic. The majority occurred within 100 days of AHCT (86%) and median time from tunneled line placement to CRT was 44 days (range, 11 to 89 days). Outcomes of these 50 patients with CRT were compared with age- and disease-matched AHCT control subjects to identify risk factors. History of prior venous thromboembolism (VTE) (20.9% versus 7.0%, P =.02) was the only significant risk factor. Treatment with low-molecular-weight heparin was tolerated with rare minor bleeding (4%), although CRT recurrence or extension (10%) and subsequent VTE (12%) were common. CRT did not impact on nonrelapse mortality or risk of relapse; 2-year progression-free survival was 55% in CRT cases versus 54% in control subjects (P =.42). CRT appears to be common in patients with lymphoma and myeloma undergoing AHCT and significantly contributes to morbidity. Further study to determine mitigating strategies and modify risk factors for CRT is warranted.

Original languageEnglish (US)
Pages (from-to)e20-e25
JournalBiology of Blood and Marrow Transplantation
Volume24
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Stem Cell Transplantation
Lymphoma
Thrombosis
Catheters
Cell Transplantation
Venous Thromboembolism
Recurrence
Low Molecular Weight Heparin
Incidence
Risk Management
Disease-Free Survival
Hemorrhage
Morbidity
Mortality

Keywords

  • Autologous transplantation
  • Catheter-related thrombosis
  • Lymphoma

Cite this

Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation. / Hegerova, Livia; Bachan, Adam; Cao, Qing; Vu, Huong X.; Rogosheske, John; Reding, Mark T; Brunstein, Claudio G; Arora, Mukta; Ustun, Celalettin; Vercellotti, Gregory M; Bachanova, Veronika.

In: Biology of Blood and Marrow Transplantation, Vol. 24, No. 12, 01.12.2018, p. e20-e25.

Research output: Contribution to journalArticle

@article{46c761742636499da52c09df97bb6b60,
title = "Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation",
abstract = "Catheter-related thrombosis (CRT) occurs frequently during autologous hematopoietic cell transplantation (AHCT) and data regarding the incidence, risk factors, and management are understudied. We evaluated 789 consecutive patients with lymphoma and myeloma that underwent AHCT over 10 years (2006 to 2016) and detected the incidence of CRT was 6.3{\%}; only 32{\%} of CRT were symptomatic. The majority occurred within 100 days of AHCT (86{\%}) and median time from tunneled line placement to CRT was 44 days (range, 11 to 89 days). Outcomes of these 50 patients with CRT were compared with age- and disease-matched AHCT control subjects to identify risk factors. History of prior venous thromboembolism (VTE) (20.9{\%} versus 7.0{\%}, P =.02) was the only significant risk factor. Treatment with low-molecular-weight heparin was tolerated with rare minor bleeding (4{\%}), although CRT recurrence or extension (10{\%}) and subsequent VTE (12{\%}) were common. CRT did not impact on nonrelapse mortality or risk of relapse; 2-year progression-free survival was 55{\%} in CRT cases versus 54{\%} in control subjects (P =.42). CRT appears to be common in patients with lymphoma and myeloma undergoing AHCT and significantly contributes to morbidity. Further study to determine mitigating strategies and modify risk factors for CRT is warranted.",
keywords = "Autologous transplantation, Catheter-related thrombosis, Lymphoma",
author = "Livia Hegerova and Adam Bachan and Qing Cao and Vu, {Huong X.} and John Rogosheske and Reding, {Mark T} and Brunstein, {Claudio G} and Mukta Arora and Celalettin Ustun and Vercellotti, {Gregory M} and Veronika Bachanova",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.bbmt.2018.07.028",
language = "English (US)",
volume = "24",
pages = "e20--e25",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation

AU - Hegerova, Livia

AU - Bachan, Adam

AU - Cao, Qing

AU - Vu, Huong X.

AU - Rogosheske, John

AU - Reding, Mark T

AU - Brunstein, Claudio G

AU - Arora, Mukta

AU - Ustun, Celalettin

AU - Vercellotti, Gregory M

AU - Bachanova, Veronika

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Catheter-related thrombosis (CRT) occurs frequently during autologous hematopoietic cell transplantation (AHCT) and data regarding the incidence, risk factors, and management are understudied. We evaluated 789 consecutive patients with lymphoma and myeloma that underwent AHCT over 10 years (2006 to 2016) and detected the incidence of CRT was 6.3%; only 32% of CRT were symptomatic. The majority occurred within 100 days of AHCT (86%) and median time from tunneled line placement to CRT was 44 days (range, 11 to 89 days). Outcomes of these 50 patients with CRT were compared with age- and disease-matched AHCT control subjects to identify risk factors. History of prior venous thromboembolism (VTE) (20.9% versus 7.0%, P =.02) was the only significant risk factor. Treatment with low-molecular-weight heparin was tolerated with rare minor bleeding (4%), although CRT recurrence or extension (10%) and subsequent VTE (12%) were common. CRT did not impact on nonrelapse mortality or risk of relapse; 2-year progression-free survival was 55% in CRT cases versus 54% in control subjects (P =.42). CRT appears to be common in patients with lymphoma and myeloma undergoing AHCT and significantly contributes to morbidity. Further study to determine mitigating strategies and modify risk factors for CRT is warranted.

AB - Catheter-related thrombosis (CRT) occurs frequently during autologous hematopoietic cell transplantation (AHCT) and data regarding the incidence, risk factors, and management are understudied. We evaluated 789 consecutive patients with lymphoma and myeloma that underwent AHCT over 10 years (2006 to 2016) and detected the incidence of CRT was 6.3%; only 32% of CRT were symptomatic. The majority occurred within 100 days of AHCT (86%) and median time from tunneled line placement to CRT was 44 days (range, 11 to 89 days). Outcomes of these 50 patients with CRT were compared with age- and disease-matched AHCT control subjects to identify risk factors. History of prior venous thromboembolism (VTE) (20.9% versus 7.0%, P =.02) was the only significant risk factor. Treatment with low-molecular-weight heparin was tolerated with rare minor bleeding (4%), although CRT recurrence or extension (10%) and subsequent VTE (12%) were common. CRT did not impact on nonrelapse mortality or risk of relapse; 2-year progression-free survival was 55% in CRT cases versus 54% in control subjects (P =.42). CRT appears to be common in patients with lymphoma and myeloma undergoing AHCT and significantly contributes to morbidity. Further study to determine mitigating strategies and modify risk factors for CRT is warranted.

KW - Autologous transplantation

KW - Catheter-related thrombosis

KW - Lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85052751845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052751845&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.07.028

DO - 10.1016/j.bbmt.2018.07.028

M3 - Article

VL - 24

SP - e20-e25

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 12

ER -